Basket | Login


Science watch


Our science watch section reports on the story behind the media-reported “breakthrough” headlines in dementia, by focusing on the original journal study. Reports of other developments in research on care and cure are also included.

13/10/2021 Anavex Life Sciences announces the continuation of its Phase IIb/III study for AD following recommendation of the Independent Data Safety Monitoring Board
08/10/2021 Roche has been granted US FDA Grants Breakthrough Therapy designation for gantenerumab in AD
06/10/2021 Cassava Sciences initiates a Phase III trial of simufilam for Alzheimer’s disease
21/09/2021 TouchNEUROLOGY discusses the approval of aducanumab for Alzheimer’s disease, with two experts in the field
20/09/2021 Gates Notes post highlights the need for early diagnostics for Alzheimer's disease and dementia
13/09/2021 New study by Women's Brain Project finds clinical trials in Alzheimer’s disease enrol less women than expected and less than in the past
07/09/2021 Alpha Cognition receives FDA approval to proceed with the clinical development of Alpha-1062 for AD
02/09/2021 Gabriel de Erausquin discusses impact of COVID-19 on long-term cognitive dysfunction and acceleration of AD symptoms
01/09/2021 New research in JAMA Neurology explores the impact of sleep duration on amyloid accumulation and cognitive performance
31/08/2021 AC Immune announces top-line results from LAURIET, their Phase 2 trial of semorinemab
25/08/2021 Cortexyme presents new analyses of its GAIN Phase II/III trial for AD
19/08/2021 Having a cognitively stimulating job might reduce the risk of developing dementia, according to new research in the BMJ
11/08/2021 Researchers identify a new genetic mutation that causes a form of early-onset, fast-progressing Alzheimer's disease
30/07/2021 Highlights from the Alzheimer's Association International Conference 2021
29/07/2021 Biogen and Eisai announce the design of the observational study evaluating the effectiveness and safety of aducanumab